Cancer Vaccines: From First-in-Class to Best-in-Class?

  • March 2013
  • -
  • Bioseeker
  • -
  • 1007 pages

This report gives you a new and unique way of stratifying and analyzing the global cancer vaccine pipeline and presents actionable analysis which allows you to discover:

* Where the competition is; Which targets, tumor types and companies are setting the path?
* What is first-in-class in the cancer vaccine pipeline?
* Is First-in-Class the Best-in-Class?
* Indication expansion opportunities
* Drug repositioning opportunities
* Which pathways are targeted, by what and how?
* Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

BioSeeker builds its analysis on a comprehensive base of 196 cancer vaccine drugs from within the portfolio of 114 companies world-wide, from Ceased to Marketed. We have identified 137 drug targets, which we have organized into 114 drug target strategies and assessed them in 52 tumor types. Our pipeline analysis has five levels:

1) Target Atlas: Shows you how individual targets tie into different target strategies and their subsequent R&D progress.

2) First-in-Class to Best-in-Class: Shows you the progress and maturation of different target strategies. Identifies which target strategies are new and unique from one developmental stage to the next.

3) Compound Type: Shows you the competitive landscape of target strategies from a compound perspective, including crossover analysis of target strategies among different compound types.

4) Indication Selection: Shows the distribution and deployment of target strategies by cancer indications. The competitive level in each cancer indication is assessed.

5) Competitive Landscape: Provides a cross-examination of each company’s entire pipeline on the basis of its defined drug target strategies, including a Competitive Fall-Out analysis and a corporate pipeline ranking based on 15 parameters.

Our Analysis includes:

* Head-to-head target competing analysis
* Significant drug target overlap analysis
* Cross-sectional R&D profiling of individual drug targets.
* Cross-over analysis of target strategies among different tumor types.
* Competitive Fall-Out analysis of the entire company pipeline: Answering three core questions about each company’s pipeline:
- Where are we?
- Where is our general and specific competition?
- What is the level of competition where we want to be?
* 15 parameter deep corporate pipeline ranking, including both internal and external pipeline factors.

The report serves as an external commercial advocate for your company’s interest in the cancer vaccine pipeline by:

* Better identifying benchmarking peers
* Providing rationale for in/out licensing decisions of drug candidates
* Performing proper drug due diligence
* Strategies for commercial planning
* Guiding Research & Development efforts

Table Of Contents

Table of Contents

1 Executive Summary 3
2 About Cancer Highlights - A Module of the DevOnc Platform 5
2.1 Cancer Focus Areas 5
2.2 Subscribe Today and Start Saving 6
2.2.1 Type of License 6
2.3 Additional Information 6
2.4 BioSeeker Group’s Oncology Team 6
3 Methodology 7
3.1 Cancer Highlights’ Five Pillar Drug Assessment 7
4 Table of Contents 9
4.1 List of Figures 19
4.2 List of Tables 19
5 Introduction 28
5.1 The Scope of this Report 28
5.2 Definitions 31
5.3 Abbreviations 31
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment 32
6.1 Drug Repositioning in Oncology 32
6.2 Introduction to Targets of Cancer Vaccine Drugs 33
6.2.1 Acid Phosphatase Activity Targets 38
6.2.2 Carboxypeptidase Activity Targets 39
6.2.3 Catalytic Activity Targets 41
6.2.4 Cell Adhesion Molecule Activity Targets 43
6.2.5 Chaperone Activity Targets 52
6.2.6 Cofactor Binding Targets 54
6.2.7 Complement Activity Targets 56
6.2.8 Cytokine Activity Targets 58
6.2.9 DNA Binding Targets 68
6.2.10 DNA Topoisomerase Activity Targets 70
6.2.11 DNA-directed DNA Polymerase Activity Targets 71
6.2.12 Growth Factor Activity Targets 72
6.2.13 GTPase Activity Targets 79
6.2.14 Heat Shock Protein Activity Targets 81
6.2.15 Hormone Activity Targets 83
6.2.16 Isomerase Activity Targets 84
6.2.17 Kinase Binding Targets 85
6.2.18 Kinase Regulator Activity Targets 86
6.2.19 Metallopeptidase Activity Targets 88
6.2.20 MHC Class I Receptor Activity Targets 90
6.2.21 Molecular Function Unknown Targets 93
6.2.22 Oxidoreductase Activity Targets 112
6.2.23 Peptidase Activity Targets 114
6.2.24 Peptide Hormone Targets 123
6.2.25 Protein Binding Targets 126
6.2.26 Protein Serine/Threonine Kinase Activity Targets 128
6.2.27 Protein-tyrosine Kinase Activity Targets 130
6.2.28 Receptor Activity Targets 133
6.2.29 Receptor Binding Targets 147
6.2.30 Receptor Signaling Complex Scaffold Activity Targets 152
6.2.31 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 154
6.2.32 Receptor Signaling Protein Tyrosine Phosphatase Activity Targets 155
6.2.33 RNA-directed DNA Polymerase Activity Targets 156
6.2.34 Serine-type Peptidase Activity Targets 158
6.2.35 T Cell Receptor Activity Targets 161
6.2.36 Transcription Factor Activity Targets 164
6.2.37 Transcription Regulator Activity Targets 169
6.2.38 Translation Regulator Activity Targets 170
6.2.39 Transmembrane Receptor Activity Targets 171
6.2.40 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 173
6.2.41 Transporter Activity Targets 186
6.2.42 Other Targets 191
6.3 Mutation Profiles of Cancer Vaccine Drug Targets 201
6.3.1 Targets of Cancer Vaccine Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 201
6.4 Target-Target Interactions among Identified Targets of Cancer Vaccine Drugs 205
6.5 Protein Expression Levels of Identified Targets of Cancer Vaccine Drugs 208
6.6 The Drug-Target Competitive Landscape 210
6.7 Pathway Assessment of Cancer Vaccine Drugs 214
6.7.1 Tools for Analysis of Cancer Pathways 215
6.7.2 Pathway Assessment 216
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs 246
7.1 First-in-Class and Me-too in Marketed Drugs 249
7.2 First-in-Class and Me-too in Phase III Clinical Development 250
7.3 First-in-Class and Me-too in Phase II Clinical Development 252
7.4 First-in-Class and Me-too in Phase I Clinical Development 255
7.5 First-in-Class and Me-too in Preclinical Development 258
7.6 Drug Target Strategies of Suspended or Terminated Cancer Vaccine Drugs 261
8 Is First-in-Class the Best-in-Class? 263
8.1.1 Marketed 266
8.1.2 Phase III 269
8.1.3 Phase II 293
8.1.4 Phase I 325
8.1.5 Preclinical 339
8.1.6 Suspended 358
8.1.7 Ceased 359
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy 387
9.1 Small Molecules 389
9.1.1 Background 389
9.1.2 Target Strategies of Small Molecule Drugs 390
9.2 Peptide and Protein Drugs 392
9.2.1 Background 392
9.2.2 Target Strategies of Peptide and Protein Drugs 393
9.3 Antibodies 400
9.3.1 Background 400
9.3.2 Target Strategies of Antibody Drugs 400
9.4 Nucleic Acid Therapies 403
9.4.1 Background 403
9.4.2 Target Strategies of Nucleic Acid Drugs 404
9.5 Cell and Gene Therapy 407
9.5.1 Background 407
9.5.2 Target Strategies of Cell and Gene Therapy Drugs 408
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414
11 Selecting Indications for Cancer Vaccine Drugs 417
11.1 Acute Lymphocytic Leukemia 420
11.2 Acute Myelogenous Leukemia 421
11.3 Acute Promyelocytic Leukemia 423
11.4 Anal Dysplasia 424
11.5 B-cell Lymphoma 425
11.6 Biliary Cancer 426
11.7 Bladder Cancer 427
11.8 Bone Cancer 428
11.9 Brain Cancer 429
11.10 Breast Cancer 431
11.11 Cancer (general) 434
11.12 Cervical Cancer 435
11.13 Cervical Dysplasia 438
11.14 Chronic Myelogenous Leukemia 440
11.15 Colorectal Adenoma 441
11.16 Colorectal Cancer 442
11.17 Endometrial Cancer 445
11.18 Fallopian Tube Cancer 446
11.19 Gastrointestinal Cancer (general) 447
11.20 Gastrointestinal Stomach Cancer 448
11.21 Glioma 449
11.22 Head and Neck Cancer 450
11.23 Hematological Cancer (general) 452
11.24 Leukemia (general) 453
11.25 Liver Cancer 454
11.26 Lung Cancer (general) 455
11.27 Lymphoma (general) 458
11.28 Melanoma 459
11.29 Merkel cell carcinoma 462
11.30 Mesothelioma 463
11.31 Myelodysplastic Syndrome 464
11.32 Myeloma 465
11.33 non-Hodgkin's Lymphoma 466
11.34 Non-Small Cell Lung Cancer 467
11.35 Oesophageal Cancer 469
11.36 Osteo Sarcoma 470
11.37 Ovarian Cancer 471
11.38 Pancreatic Cancer 473
11.39 Peritoneal Cancer 475
11.40 Prostate Cancer 476
11.41 Radio/chemotherapy-induced Bone Marrow Injury (general) 479
11.42 Renal Cancer 480
11.43 Sarcoma (general) 482
11.44 Skin Cancer (general) 483
11.45 Small Cell Lung Cancer 484
11.46 Soft Tissue Sarcoma 485
11.47 Solid Tumor 486
11.48 Squamous Cell Carcinoma 487
11.49 T-cell Lymphoma 488
11.50 Thyroid Cancer 489
11.51 Unspecified Cancer Indication 490
11.52 Vaccine adjunct 492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company 493
12.1 Changes in the Competitive Landscape: MandA, Bankruptcy and Name Change 496
12.2 Company Facts and Ranking 498
12.3 Competitive Fall-Out Assessment 505
12.4 AC Immune 507
12.5 Adaptimmune 510
12.6 Advaxis 515
12.7 Agenus 523
12.8 Aida Pharmaceuticals 528
12.9 AlphaVax 531
12.10 Amgen 538
12.11 Anza Therapeutics 541
12.12 Argos Therapeutics 545
12.13 Astellas 548
12.14 AstraZeneca 551
12.15 Bavarian Nordic 554
12.16 Bellicum Pharmaceuticals 560
12.17 Biogen Idec 563
12.18 BioNTech 567
12.19 BioSante 570
12.20 Biostar 575
12.21 BioVex 578
12.22 BreakThrough Therapeutics 581
12.23 Bristol-Myers Squibb 584
12.24 Cancer Advances 587
12.25 Cancer Research Technology 590
12.26 Celldex Therapeutics 597
12.27 Center of Molecular Immunology 603
12.28 CG Therapeutics 606
12.29 Cosmo Pharmaceuticals 611
12.30 CreaGene 616
12.31 CSL 619
12.32 CureVac 623
12.33 Dainippon Sumitomo Pharma 627
12.34 Dendreon 632
12.35 DeveloGen 641
12.36 Eisai 644
12.37 Eli Lilly 647
12.38 EntreMed 650
12.39 Epeius Biotechnologies 653
12.40 Etubics 656
12.41 Galena Biopharma 664
12.42 Generex 671
12.43 GenOdyssee Pharmaceuticals 677
12.44 Genticel 680
12.45 Geron 684
12.46 GlaxoSmithKline 691
12.47 Gliknik 700
12.48 GlobeImmune 703
12.49 Gradalis 709
12.50 Heat Biologics 712
12.51 Hemispherx Biopharma 715
12.52 Hoffmann-La Roche 718
12.53 Ichor Medical Systems 721
12.54 Idera Pharmaceuticals 726
12.55 immatics biotechnologies 731
12.56 ImmunoCellular Therapeutics 734
12.57 ImmunoFrontier 737
12.58 Immunotope 743
12.59 Immunovaccine 746
12.60 Inovio 750
12.61 Intracel 757
12.62 Introgen Therapeutics 760
12.63 ISA Pharmaceuticals 763
12.64 Jennerex Biotherapeutics 767
12.65 Johnson and Johnson 772
12.66 KAEL-GemVax 776
12.67 Lipotek 781
12.68 Mannkind 784
12.69 MediGene 789
12.70 Menarini 794
12.71 Merck KGaA 799
12.72 Micromet 802
12.73 MolMed 805
12.74 Mologen 808
12.75 Momotaro-Gene 812
12.76 Nemod Biotherapeutics 815
12.77 Neovacs 820
12.78 NIH - The US National Institute of Health 823
12.79 Non-industrial Sources 828
12.80 Northwest Biotherapeutics 837
12.81 NovaRx 841
12.82 OncoMune 844
12.83 OncoTherapy Science 847
12.84 Oncothyreon 850
12.85 Oncovir 858
12.86 Onyvax 861
12.87 Orchestra Therapeutics 864
12.88 Oxford BioMedica 867
12.89 Pepscan Therapeutics 872
12.90 Peptagen 877
12.91 Pfizer 880
12.92 PharmaForm 884
12.93 Pharmexa 889
12.94 Progenics Pharmaceuticals 897
12.95 Protherics 903
12.96 Radient Pharmaceuticals 906
12.97 Receptor BioLogix 909
12.98 responsif 913
12.99 Sanofi 917
12.100 Sarepta Therapeutics 920
12.101 Scancell 925
12.102 Shionogi 928
12.103 TapImmune 931
12.104 Therion Biologics 934
12.105 Transgene 941
12.106 United Biomedical 946
12.107 Vaccinex 949
12.108 Vaxil BioTherapeutics 953
12.109 Vaximm 958
12.110 Vaxon Biotech 961
12.111 Vectura 966
12.112 Vical 969
12.113 Viragen 976
12.114 Virionics 979
12.115 ViroMed 982
12.116 Zensun 987
12.117 Zydus Cadila 990
13 Disclaimer 994
14 Drug Index 995
15 Company Index 1002



1.1 List of Figures

Figure 1: Visualization of Target-Target Interactions among Targets of Cancer Vaccine Drugs 207
Figure 2: The Drug-Target Competitive Landscape of Cancer Vaccine Drugs - Large Cluster 211
Figure 3: The Drug-Target Competitive Landscape Cancer Vaccine Drugs - Smaller Clusters 212
Figure 4: Head-to-Head Targeting Competitive Landscape of Cancer Vaccine Drugs 213
Figure 5: Number of Companies per Ranking Level 500



1.2 List of Tables

Table 1: Cancer Highlights’ Five Pillar Drug Assessment 7
Table 2: Breakdown of the Included Cancer Vaccine Drug Pipeline by Stage of Development 28
Table 3: Head to Head Target Competition among Cancer Vaccine Drugs 28
Table 4: Overview of Drug Target Strategy Themes 33
Table 5: Ceased Targets of Cancer Vaccine Drugs 34
Table 6: Official Gene Symbol to Target Profle 35
Table 7: Mutation Frequencies of Cancer Vaccine Drug Targets 202
Table 8: Number of Target-Target Interactions among Targets of Cancer Vaccine Drugs 206
Table 9: Available Protein Expression Profiles of Cancer Vaccine Drug Targets 208
Table 10: Pathway Summary 216
Table 11: Drug Targets without any Identified Assigned Pathways 216
Table 12: Pathway Profiles According to BioCarta of Cancer Vaccine Drug Targets 218
Table 13: Pathway Profiles According to KEGG of Cancer Vaccine Drug Targets 226
Table 14: Pathway Profiles According to NetPath of Cancer Vaccine Drug Targets 243
Table 15: First-in-Class Analysis of Drug Target Strategies 247
Table 16: Top Competitive Target Strategies of Cancer Vaccine Drugs 247
Table 17: First-in-Class and Me-too of Cancer Vaccine Drugs being Marketed 249
Table 18: First-in-Class and Me-too of Cancer Vaccine Drugs in Phase III Clinical 250
Table 19: The Competition Through Close Mechanistic Approximation Between Phase III Cancer Vaccine Drugs 251
Table 20: First-in-Class and Me-too of Cancer Vaccine Drugs in Phase II Clinical Development 252
Table 21: The Competition Through Close Mechanistic Approximation Between Phase II Cancer Vaccine Drugs 254
Table 22: First-in-Class and Me-too of Cancer Vaccine Drugs in Phase I Clinical Development 255
Table 23: The Competition Through Close Mechanistic Approximation Between Phase I Cancer Vaccine Drugs 257
Table 24: First-in-Class and Me-too of Cancer Vaccine Drugs in Preclinical Development 258
Table 25: The Competition Through Close Mechanistic Approximation Between Preclinical Cancer Vaccine Drugs 259
Table 26: Target Strategies of No Data, Suspended or Terminated Cancer Vaccine Drugs 261
Table 27: Finding Competitive Profile for Best-in-Class Consideration 263
Table 28: Overview of Compound Strategy Competition Among Cancer Vaccine Drugs 388
Table 29: Overview of the Competitive Landscape of Small Molecule Based Cancer Vaccine Drugs 390
Table 30: Pursued Target Strategies of Small Molecule Drugs Based Cancer Vaccine Drugs 391
Table 31: Overview of the Competitive Landscape of Peptide Based Cancer Vaccine Drugs 393
Table 32: Competitive Comparison of Target Strategies of Peptide Based Cancer Vaccine Drugs 394
Table 33: Pursued Target Strategies of Peptide Based Cancer Vaccine Drugs 395
Table 34: Overview of the Competitive Landscape of Protein Based Cancer Vaccine Drugs 397
Table 35: Competitive Comparison of Target Strategies of Protein Based Cancer Vaccine Drugs 398
Table 36: Pursued Target Strategies of Protein Based Cancer Vaccine Drugs 398
Table 37: Overview of the Competitive Landscape of Antibody Based Cancer Vaccine Drugs 400
Table 38: Competitive Comparison of Target Strategies of Antibody Based Cancer Vaccine Drugs 401
Table 39: Pursued Target Strategies of Antibody Based Cancer Vaccine Drugs 401
Table 40: Overview of the Competitive Landscape of Nucleic Acid Based Cancer Vaccine Drugs 404
Table 41: Competitive Comparison of Target Strategies of Nucleic Acid Based Cancer Vaccine Drugs 405
Table 42: Pursued Target Strategies of Nucleic Acid Based Cancer Vaccine Drugs 405
Table 43: Potential Forms of Cell Therapy 407
Table 44: Vectors in Gene Therapy 408
Table 45: Overview of the Competitive Landscape of Cell Therapy Based Cancer Vaccine Drugs 408
Table 46: Competitive Comparison of Target Strategies of Cell Therapy Based Cancer Vaccine Drugs 409
Table 47: Pursued Target Strategies of Cell Therapy Based Cancer Vaccine Drugs 409
Table 48: Overview of the Competitive Landscape of Gene Therapy Based Cancer Vaccine Drugs 410
Table 49: Competitive Comparison of Target Strategies of Gene Therapy Based Cancer Vaccine Drugs 411
Table 50: Pursued Target Strategies of Gene Therapy Based Cancer Vaccine Drugs 412
Table 51: The Competition Through Close Mechanistic Approximation Among Cancer Vaccine Drugs 414
Table 52 Competitive Summary by Indication of Cancer Vaccine Drugs 418
Table 53: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Acute Lymphocytic Leukemia 420
Table 54: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Acute Myelogenous Leukemia 421
Table 55: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs 421
Table 56: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Acute Promyelocytic Leukemia 423
Table 57: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Anal Dysplasia 424
Table 58: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of B-cell Lymphoma 425
Table 59: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Biliary Cancer 426
Table 60: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Bladder Cancer 427
Table 61: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Bone Cancer 428
Table 62: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Brain Cancer 429
Table 63: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs 429
Table 64: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Breast Cancer 431
Table 65: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 432
Table 66: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Cancer (general) 434
Table 67: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Cervical Cancer 435
Table 68: The Competition through Close Mechanistic Approximation between Cervical Cancer Drugs 437
Table 69: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Cervical Dysplasia 438
Table 70: The Competition through Close Mechanistic Approximation between Cervical Dysplasia Drugs 439
Table 71: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Chronic Myelogenous Leukemia 440
Table 72: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Colorectal Adenoma 441
Table 73: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Colorectal Cancer 442
Table 74: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs 443
Table 75: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Endometrial Cancer 445
Table 76: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Fallopian Tube Cancer 446
Table 77: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Gastrointestinal Cancer (general) 447
Table 78: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Gastrointestinal Stomach Cancer 448
Table 79: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Glioma 449
Table 80: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Head and Neck Cancer 450
Table 81: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs 450
Table 82: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Hematological Cancer (general) 452
Table 83: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Leukemia (general) 453
Table 84: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Liver Cancer 454
Table 85: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 454
Table 86: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Lung Cancer (general) 455
Table 87: The Competition through Close Mechanistic Approximation between Lung Cancer (general) Drugs 457
Table 88: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Lymphoma (general) 458
Table 89: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Melanoma 459
Table 90: The Competition through Close Mechanistic Approximation between Melanoma Drugs 460
Table 91: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Merkel cell carcinoma 462
Table 92: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Mesothelioma 463
Table 93: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Myelodysplastic Syndrome 464
Table 94: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Myeloma 465
Table 95: The Competition through Close Mechanistic Approximation between Myeloma Drugs 465
Table 96: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of non-Hodgkin's Lymphoma 466
Table 97: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Non-Small Cell Lung Cancer 467
Table 98: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs 468
Table 99: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Oesophageal Cancer 469
Table 100: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Osteo Sarcoma 470
Table 101: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Ovarian Cancer 471
Table 102: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 472
Table 103: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Pancreatic Cancer 473
Table 104: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 474
Table 105: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Peritoneal Cancer 475
Table 106: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Prostate Cancer 476
Table 107: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 477
Table 108: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Radio/chemotherapy-induced Bone Marrow Injury (general) 479
Table 109: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Renal Cancer 480
Table 110: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs 481
Table 111: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Sarcoma (general) 482
Table 112: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Skin Cancer (general) 483
Table 113: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Small Cell Lung Cancer 484
Table 114: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Soft Tissue Sarcoma 485
Table 115: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Solid Tumor 486
Table 116: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Squamous Cell Carcinoma 487
Table 117: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of T-cell Lymphoma 488
Table 118: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Thyroid Cancer 489
Table 119: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Unspecified Cancer Indication 490
Table 120: The Competition through Close Mechanistic Approximation between Unspecified Cancer Indication Drugs 491
Table 121: Target Strategy Development Profiles of Cancer Vaccine Drugs as Vaccine adjunct 492
Table 122: Competitive Summary by Company of Cancer Vaccine Drug Development 493
Table 123: Summary Table of Corporate Changes in the Competitive Landscape of Cancer Vaccine Drug Development 496
Table 124: The Worst Ranking and the Highest Populated Level for Each of the 15 Ranking Parameters 499
Table 125: Example of a Competitive Fall-Out Table (Targeting TERT Modified) 505
Table 126: AC Immune's Included Cancer Vaccine Drugs and Competitive Fall-Out 508
Table 127: Adaptimmune's Included Cancer Vaccine Drugs and Competitive Fall-Out 512
Table 128: Advaxis’ Included Cancer Vaccine Drugs and Competitive Fall-Out 518
Table 129: Agenus’ Included Cancer Vaccine Drugs and Competitive Fall-Out 525
Table 130: Aida Pharmaceuticals’ Included Cancer Vaccine Drugs and Competitive Fall-Out 529
Table 131: AlphaVax's Included Cancer Vaccine Drugs and Competitive Fall-Out 533
Table 132: Amgen's Included Cancer Vaccine Drugs and Competitive Fall-Out 539
Table 133: Anza Therapeutics’ Included Cancer Vaccine Drugs and Competitive Fall-Out 543
Table 134: Argos Therapeutics’ Included Cancer Vaccine Drugs and Competitive Fall-Out 546
Table 135: Astellas’ Included Cancer Vaccine Drugs and Competitive Fall-Out 549
Table 136: AstraZeneca's Included Cancer Vaccine Drugs and Competitive Fall-Out 552
Table 137: Bavarian Nordic's Included Cancer Vaccine Drugs and Competitive Fall-Out 556
Table 138: Bellicum Pharmaceuticals’ Included Cancer Vaccine Drugs and Competitive Fall-Out 561
Table 139: Biogen Idec's Included Cancer Vaccine Drugs and Competitive Fall-Out 565
Table 140: BioNTech's Included Cancer Vaccine Drugs and Competitive Fall-Out 568
Table 141: BioSante's Included Cancer Vaccine Drugs and Competitive Fall-Out 572
Table 142: Biostar's Included Cancer Vaccine Drugs and Competitive Fall-Out 576
Table 143: BioVex's Included Cancer Vaccine Drugs and Competitive Fall-Out 579
Table 144: BreakThrough Therapeutics’ Included Cancer Vaccine Drugs and Competitive Fall-Out 582
Table 145: Bristol-Myers Squibb's Included Cancer Vaccine Drugs and Competitive Fall-Out 585
Table 146: Cancer Advances’ Included Cancer Vaccine Drugs and Competitive Fall-Out 588
Table 147: Cancer Research Technology's Included Cancer Vaccine Drugs and Competitive Fall-Out 592
Table 148: Celldex Therapeutics’ Included Cancer Vaccine Drugs and Competitive Fall-Out 599
Table 149: Center of Molecular Immunology's Included Cancer Vaccine Drugs and Competitive Fall-Out 604
Table 150: CG Therapeutics’ Included Cancer Vaccine Drugs and Competitive Fall-Out 608
Table 151: Cosmo Pharmaceuticals’ Included Cancer Vaccine Drugs and Competitive Fall-Out 613
Table 152: CreaGene's Included Cancer Vaccine Drugs and Competitive Fall-Out 617
Table 153: CSL's Included Cancer Vaccine Drugs and Competitive Fall-Out 621
Table 154: CureVac's Included Cancer Vaccine Drugs and Competitive Fall-Out 624
Table 155: Dainippon Sumitomo Pharma's Included Cancer Vaccine Drugs and Competitive Fall-Out 629
Table 156: Dendreon's Included Cancer Vaccine Drugs and Competitive Fall-Out 635
Table 157: DeveloGen's Included Cancer Vaccine Drugs and Competitive Fall-Out 642
Table 158: Eisai's Included Cancer Vaccine Drugs and Competitive Fall-Out 645
Table 159: Eli Lilly's Included Cancer Vaccine Drugs and Competitive Fall-Out 648
Table 160: EntreMed's Included Cancer Vaccine Drugs and Competitive Fall-Out 651
Table 161: Epeius Biotechnologies’ Included Cancer Vaccine Drugs and Competitive Fall-Out 654
Table 162: Etubics’ Included Cancer Vaccine Drugs and Competitive Fall-Out 659
Table 163: Galena Biopharma's Included Cancer Vaccine Drugs and Competitive Fall-Out 667
Table 164: Generex's Included Cancer Vaccine Drugs and Competitive Fall-Out 673
Table 165: GenOdyssee Pharmaceuticals’ Included Cancer Vaccine Drugs and Competitive Fall-Out 678
Table 166: Genticel's Included Cancer Vaccine Drugs and Competitive Fall-Out 682
Table 167: Geron's Included Cancer Vaccine Drugs and Competitive Fall-Out 686
Table 168: GlaxoSmithKline's Included Cancer Vaccine Drugs and Competitive Fall-Out 694
Table 169: Gliknik's Included Cancer Vaccine Drugs and Competitive Fall-Out 701
Table 170: GlobeImmune's Included Cancer Vaccine Drugs and Competitive Fall-Out 705
Table 171: Gradalis’ Included Cancer Vaccine Drugs and Competitive Fall-Out 710
Table 172: Heat Biologics’ Included Cancer Vaccine Drugs and Competitive Fall-Out 713
Table 173: Hemispherx Biopharma's Included Cancer Vaccine Drugs and Competitive Fall-Out 716
Table 174: Hoffmann-La Roche's Included Cancer Vaccine Drugs and Competitive Fall-Out 719
Table 175: Ichor Medical Systems’ Included Cancer Vaccine Drugs and Competitive Fall-Out 723
Table 176: Idera Pharmaceuticals’ Included Cancer Vaccine Drugs and Competitive Fall-Out 728
Table 177: immatics biotechnologies’ Included Cancer Vaccine Drugs and Competitive Fall-Out 732
Table 178: ImmunoCellular Therapeutics’ Included Cancer Vaccine Drugs and Competitive Fall-Out 735
Table 179: ImmunoFrontier's Included Cancer Vaccine Drugs and Competitive Fall-Out 739
Table 180: Immunotope's Included Cancer Vaccine Drugs and Competitive Fall-Out 744
Table 181: Immunovaccine's Included Cancer Vaccine Drugs and Competitive Fall-Out 748
Table 182: Inovio's Included Cancer Vaccine Drugs and Competitive Fall-Out 752
Table 183: Intracel's Included Cancer Vaccine Drugs and Competitive Fall-Out 758
Table 184: Introgen Therapeutics’ Included Cancer Vaccine Drugs and Competitive Fall-Out 761
Table 185: ISA Pharmaceuticals’ Included Cancer Vaccine Drugs and Competitive Fall-Out 764
Table 186: Jennerex Biotherapeutics’ Included Cancer Vaccine Drugs and Competitive Fall-Out 769
Table 187: Johnson and Johnson's Included Cancer Vaccine Drugs and Competitive Fall-Out 774
Table 188: KAEL-GemVax's Included Cancer Vaccine Drugs and Competitive Fall-Out 778
Table 189: Lipotek's Included Cancer Vaccine Drugs and Competitive Fall-Out 782
Table 190: Mannkind's Included Cancer Vaccine Drugs and Competitive Fall-Out 786
Table 191: MediGene's Included Cancer Vaccine Drugs and Competitive Fall-Out 791
Table 192: Menarini's Included Cancer Vaccine Drugs and Competitive Fall-Out 796
Table 193: Merck KGaA's Included Cancer Vaccine Drugs and Competitive Fall-Out 800
Table 194: Micromet's Included Cancer Vaccine Drugs and Competitive Fall-Out 803
Table 195: MolMed's Included Cancer Vaccine Drugs and Competitive Fall-Out 806
Table 196: Mologen's Included Cancer Vaccine Drugs and Competitive Fall-Out 809
Table 197: Momotaro-Gene's Included Cancer Vaccine Drugs and Competitive Fall-Out 813
Table 198: Nemod Biotherapeutics’ Included Cancer Vaccine Drugs and Competitive Fall-Out 817
Table 199: Neovacs’ Included Cancer Vaccine Drugs and Competitive Fall-Out 821
Table 200: NIH's Included Cancer Vaccine Drugs and Competitive Fall-Out 825
Table 201: Non-industrial source's Included Cancer Vaccine Drugs and Competitive Fall-Out 830
Table 202: Northwest Biotherapeutics’ Included Cancer Vaccine Drugs and Competitive Fall-Out 839
Table 203: NovaRx's Included Cancer Vaccine Drugs and Competitive Fall-Out 842
Table 204: OncoMune's Included Cancer Vaccine Drugs and Competitive Fall-Out 845
Table 205: OncoTherapy Science's Included Cancer Vaccine Drugs and Competitive Fall-Out 848
Table 206: Oncothyreon's Included Cancer Vaccine Drugs and Competitive Fall-Out 852
Table 207: Oncovir's Included Cancer Vaccine Drugs and Competitive Fall-Out 859
Table 208: Onyvax's Included Cancer Vaccine Drugs and Competitive Fall-Out 862
Table 209: Orchestra Therapeutics’ Included Cancer Vaccine Drugs and Competitive Fall-Out 865
Table 210: Oxford BioMedica's Included Cancer Vaccine Drugs and Competitive Fall-Out 869
Table 211: Pepscan Therapeutics’ Included Cancer Vaccine Drugs and Competitive Fall-Out 874
Table 212: Peptagen's Included Cancer Vaccine Drugs and Competitive Fall-Out 878
Table 213: Pfizer's Included Cancer Vaccine Drugs and Competitive Fall-Out 882
Table 214: PharmaForm's Included Cancer Vaccine Drugs and Competitive Fall-Out 886
Table 215: Pharmexa's Included Cancer Vaccine Drugs and Competitive Fall-Out 891
Table 216: Progenics Pharmaceuticals’ Included Cancer Vaccine Drugs and Competitive Fall-Out 899
Table 217: Protherics’ Included Cancer Vaccine Drugs and Competitive Fall-Out 904
Table 218: Radient Pharmaceuticals’ Included Cancer Vaccine Drugs and Competitive Fall-Out 907
Table 219: Receptor BioLogix's Included Cancer Vaccine Drugs and Competitive Fall-Out 911
Table 220: responsif's Included Cancer Vaccine Drugs and Competitive Fall-Out 915
Table 221: Sanofi's Included Cancer Vaccine Drugs and Competitive Fall-Out 918
Table 222: Sarepta Therapeutics’ Included Cancer Vaccine Drugs and Competitive Fall-Out 922
Table 223: Scancell's Included Cancer Vaccine Drugs and Competitive Fall-Out 926
Table 224: Shionogi's Included Cancer Vaccine Drugs and Competitive Fall-Out 929
Table 225: TapImmune's Included Cancer Vaccine Drugs and Competitive Fall-Out 932
Table 226: Therion Biologics’ Included Cancer Vaccine Drugs and Competitive Fall-Out 936
Table 227: Transgene's Included Cancer Vaccine Drugs and Competitive Fall-Out 943
Table 228: United Biomedical's Included Cancer Vaccine Drugs and Competitive Fall-Out 947
Table 229: Vaccinex's Included Cancer Vaccine Drugs and Competitive Fall-Out 950
Table 230: Vaxil BioTherapeutics’ Included Cancer Vaccine Drugs and Competitive Fall-Out 955
Table 231: Vaximm's Included Cancer Vaccine Drugs and Competitive Fall-Out 959
Table 232: Vaxon Biotech's Included Cancer Vaccine Drugs and Competitive Fall-Out 963
Table 233: Vectura's Included Cancer Vaccine Drugs and Competitive Fall-Out 967
Table 234: Vical's Included Cancer Vaccine Drugs and Competitive Fall-Out 971
Table 235: Viragen's Included Cancer Vaccine Drugs and Competitive Fall-Out 977
Table 236: Virionics’ Included Cancer Vaccine Drugs and Competitive Fall-Out 980
Table 237: ViroMed's Included Cancer Vaccine Drugs and Competitive Fall-Out 984
Table 238: Zensun's Included Cancer Vaccine Drugs and Competitive Fall-Out 988
Table 239: Zydus Cadila's Included Cancer Vaccine Drugs and Competitive Fall-Out 992

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023

  • $ 9 995
  • Industry report
  • March 2014
  • by Global Data

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023 Summary The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected ...

Antibiotics: Technologies and Global Markets

Antibiotics: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Identify the major market trends and the factors driving or inhibiting the growth of the global pharmaceutical antibiotics market and its various submarkets. - Learn about developments ...

Antifungal Drugs : Technologies and Global Markets

Antifungal Drugs : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This report aims to determine the current status of the global human antifungal market and assess its growth potential over the five-year period from 2013 through 2018. It covers approved human therapeutics ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.